KAM
NTLA icon

Kazazian Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Kazazian Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12,530
Closed -$359K – 76
2018
Q3 		$359K Hold
12,530
– – 0.34% 55
2018
Q2 		$343K Buy
12,530
+2,773
+28% +$67.2K 0.31% 64
2018
Q1 		$206K Buy
+9,757
New +$240K 0.22% 73

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Kazazian Asset Management's NTLA Position: Q4 2018 in Review

Kazazian Asset Management sold out of Intellia Therapeutics (NTLA) in Q4 2018, closing a stake of 12,530 shares — an estimated $359K sold.

Kazazian Asset Management first reported a position in NTLA in Q1 2018 and held it in 3 quarters. The position peaked at $359K in Q3 2018. 141 funds tracked by Wall St. Rank hold NTLA as of Q4 2018.

  • Kazazian Asset Management reported no remaining Intellia Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Kazazian Asset Management sold 12,530 Intellia Therapeutics shares in Q4 2018, an estimated $359K.
  • Kazazian Asset Management first reported a position in Intellia Therapeutics in Q1 2018 and held it in 3 quarters.
  • Kazazian Asset Management's Intellia Therapeutics position peaked at $359K in Q3 2018.
  • 141 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2018.

Based on Kazazian Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.